Abstract
Cellular senescence is enhanced in a number of chronic
diseases. Several studies have now linked senescent cells to chronic disease pathology
and have shown that inhibition/removal of these cells ameliorates disease in relevant models. Senescent
cells undergo a form of cell cycle arrest that results in transcriptional and
metabolic changes that enhances cellular morphology, cell cycle arrest markers
such as p21 and p16 and produce a Senescence Associated Secretory Phenotype
(SASP) which includes secretion of cytokines, chemokines and proteases that are
thought to contribute to disease pathogenesis. One such debilitating disease is
Chronic Obstructive Pulmonary Disease (COPD), where senescent cells are increased
and believed to contribute to the disease. In order to identify modulators of
cellular senescence for the treatment of COPD we designed an arrayed CRISPRn screen
in primary small airway epithelial cells where we screened 250 genes to assess
their ability to modulate markers of senescence. For this, we developed a 384-well plate based, semi-automated
electroporation workflow to edit these cells using Cas9 RNP which resulted in a high editing efficiency (>90%). 72h
following electroporation the cells were treated with Etoposide for 48h to induce senescence or
DMSO as a control to measure baseline senescence levels. Careful culture
conditions and assay optimisation were required to prevent these cells from senescing
naturally to obtain a good assay window for measuring etoposide-induced
senescence. This immunofluorescence assay format enabled multiparametric
readouts including nuclear p21, enlarged morphology, cell number, cell cycle
and phospho-yH2AX foci. These endpoints not only prioritised targets for their
ability to modulate senescence, but also informed on the possible mechanisms and
safety risks associated with the targets. In addition, the ability to get
several informative endpoints from a single assay aligns with our commitment to
work more sustainably within functional genomics at AstraZeneca.